<SEC-DOCUMENT>0001564590-18-005829.txt : 20180315
<SEC-HEADER>0001564590-18-005829.hdr.sgml : 20180315
<ACCEPTANCE-DATETIME>20180315161504
ACCESSION NUMBER:		0001564590-18-005829
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180315
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180315
DATE AS OF CHANGE:		20180315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORTHOFIX INTERNATIONAL N V
		CENTRAL INDEX KEY:			0000884624
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19961
		FILM NUMBER:		18692547

	BUSINESS ADDRESS:	
		STREET 1:		7 ABRAHAM DE VEERSTRAAT
		STREET 2:		CURACAO
		CITY:			NETHERLANDS ANTILLES
		STATE:			P8
		ZIP:			00000
		BUSINESS PHONE:		214-937-2000

	MAIL ADDRESS:	
		STREET 1:		3451 PLANO PARKWAY
		CITY:			LEWISVILLE
		STATE:			TX
		ZIP:			75056
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ofix-8k_20180315.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ofix-8k_20180315.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, DC 20549 </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): March 15, 2018</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Orthofix International N.V.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Cura&#231;ao</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">0-19961</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">98-1340767</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">of incorporation) </p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">File Number) </p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Identification No.) </p></td>
</tr>
<tr>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom"  style="width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">7 Abraham de Veerstraat Cura&#231;ao</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom"  style="width:66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: 599-9-4658525</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="fis_financial_statements_and_exhibits"></a>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="font-style:italic;">see</font> General Instruction A.2. below):</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 1.01.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a><font style="text-decoration:underline;">Entry into a Material Definitive Agreement.</font> <br /><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On March 15, 2018, Orthofix International N.V. (the &#8220;Company&#8221;), through a wholly owned subsidiary (&#8220;Subsidiary&#8221;), entered into a definitive merger agreement (the &#8220;Merger Agreement&#8221;) with Spinal Kinetics Inc., a privately held developer and manufacturer of artificial cervical and lumbar discs (&#8220;Spinal Kinetics&#8221;).</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;text-decoration:underline;">Summary of the terms of the Merger Agreement:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Form of Transaction<font style="font-style:normal;">. A newly formed wholly owned subsidiary of the Company (&#8220;Merger Sub&#8221;) will merge with and into Spinal Kinetics (the &#8220;Merger&#8221;), with Spinal Kinetics remaining as the surviving corporation and a wholly owned subsidiary of the Company.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Merger Consideration<font style="font-style:normal;">. All outstanding shares </font><font style="color:#000000;font-style:normal;">of Spinal Kinetics&#8217; capital stock will be converted into the right to receive at the closing an aggregate of $45&#160;million in cash, subject to certain adjustments including the escrow fund described below, plus milestone payments of up to $60&#160;million in cash. The milestone payments include (i)&#160;up to $15 million if the U.S. Food and Drug Administration grants market clearance or approval of Spinal Kinetics&#8217; M6-C artificial cervical disc and (ii) revenue-based milestone payments of up to $45 million in connection with future sales of the M6-C artificial cervical disc and the M6-L artificial lumbar disc. Milestones must be achieved within five years of closing to trigger applicable payments. The Company expects to make the closing payments from cash on hand or available borrowing capacity.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Indemnification and Escrow.&#160;<font style="font-style:normal;">The Merger Agreement provides that the Company will be indemnified for breaches of representations and warranties as well as certain other specified matters in the Merger Agreement, subject to certain limitations in the Merger Agreement. At closing, $4.5 million of the closing merger consideration will be held in escrow to fund indemnification obligations payable during the first two years after closing. In addition, the Company generally will be entitled to offset losses against contingent milestone payments after all monies on deposit in the escrow fund have been paid out or released or are the subject of pending or unresolved indemnification claims.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Representations, Warranties and Covenants.&#160;<font style="font-style:normal;">The Merger Agreement contains customary representations, warranties and covenants of Subsidiary, Merger Sub and Spinal Kinetics. The representations and warranties of each party set forth in the Merger Agreement have been made solely for the benefit of the other parties to the Merger Agreement and such representations and warranties should not be relied on by any other person. In addition, such representations and warranties (i)&#160;have been qualified by disclosures made to the other party in connection with the Merger Agreement, (ii)&#160;are subject to the materiality standards contained in the Merger Agreement which may differ from what may be viewed as material by investors and (iii)&#160;were made only as of the date of the Merger Agreement or such other date as is specified in the Merger Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Spinal Kinetics Stockholder Approval.&#160;<font style="font-style:normal;">The Merger Agreement required the approval of Spinal Kinetics&#8217; stockholders, which was obtained by written consent promptly following the parties entering into the Merger Agreement.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Closing Conditions.&#160;<font style="font-style:normal;">The closing of the Merger is subject to the satisfaction of certain customary conditions to closing.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to file a copy of the Merger Agreement as an exhibit to its Quarterly Report on Form 10-Q for its fiscal quarter ended June&#160;30, 2018.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 7.01.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;color:#000000;">Regulation FD Disclosure</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On March 15, 2018, the Company issued a press release </font>announcing the transaction described in Item&#160;1.01 of this Current Report on Form 8-K<font style="Background-color:#FFFFFF;">.&nbsp;&nbsp;That press release is furnished herewith as Exhibit 99.1.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The information included in this Current Report on Form 8-K under this Item&#160;7.01 (including Exhibit&#160;99.1) shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Financial Statements and Exhibits</font>.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:101%;">
<tr>
<td style="width:5.24%;"></td>
<td style="width:2.19%;"></td>
<td style="width:93.57%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">(d)</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibits</font></p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">99.1</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ofix-ex991_6.htm"><font style="Background-color:#FFFFFF;text-decoration:underline;">Press Release, dated March 15, 2018.</font></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. <font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:231.35pt;;">
<tr>
<td style="width:24.2pt;"></td>
<td style="width:24.2pt;"></td>
<td style="width:181.95pt;"></td>
<td style="width:1pt;"></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix International N.V.</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Kimberley A. Elting</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kimberley A. Elting </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legal and Administrative Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: <font style="Background-color:#FFFFFF;color:#000000;">March 15, 2018</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ofix-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ofix-ex991_6.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:545.4pt;;">
<tr>
<td style="width:205.8pt;"></td>
<td style="width:132.15pt;"></td>
<td style="width:94.95pt;"></td>
<td style="width:27.45pt;"></td>
<td style="width:85.05pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031519270960711067.jpg" title="" alt="" style="width:258px;height:40px;"></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:7.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix, International N.V.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3451 Plano Parkway</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lewisville, TX 75056 USA</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel&nbsp;&nbsp; 214 937 2000</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix.com</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#004A97;font-size:36pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">News Release</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONTACT:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Mark Quick</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denise Landry</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Investor Relations</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Media Relations</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Tel&nbsp;&nbsp;&nbsp;&nbsp;214 937 2924</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel&nbsp;&nbsp; 214 937 2529</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; <font style="text-decoration:underline;">markquick@orthofix.com</font></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">deniselandry@orthofix.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Orthofix Announces Agreement to Acquire Spinal Kinetics</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Transaction to expand Orthofix&#8217;s Spine Fixation portfolio with innovative artificial disc designed to restore natural and physiologic motion to the spine.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEWISVILLE, TX. &#8211; March 15, 2018 &#8211; Orthofix International N.V. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products and value-added services today announced that it has entered into a definitive agreement to acquire Spinal Kinetics Inc., a privately held developer and manufacturer of artificial cervical and lumbar discs. Terms of the agreement include $45 million in cash closing consideration plus up to $60 million in contingent milestone payments related to U.S. Food and Drug Administration approval of the M6-C cervical disc and the achievement of trailing twelve-month sales targets of $30 million and $50 million.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;The Spinal Kinetics M6<sup style="font-size:85%; vertical-align:top">&#8482;</sup> artificial discs will further strengthen Orthofix&#8217;s product portfolio by filling a strategic gap in our Spine Fixation product line. This technology is a significant advancement in mimicking the natural motion of the spine, which we believe will be very beneficial to patients and well received by our surgeon customers,&#8221; said Orthofix President and Chief Executive Officer, Brad Mason. &#8220;This acquisition is very well aligned with our value creation strategy of accelerating topline growth by investing in faster growing market segments in our core businesses. In addition, we expect this news will energize our sales force and be attractive to potential new sales talent.&#8221;  </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Spinal Kinetics manufactures and distributes the <font style="color:#000000;">M6-C cervical and M6-L lumbar artificial discs for patients suffering from degenerative disc disease (DDD) of the spine. These unique discs are designed to mimic the anatomic structure of a natural disc by incorporating an artificial visco-elastic nucleus and fiber annulus. This allows for six degrees of motion, similar to a natural disc. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Artificial disc replacement is increasingly being indicated as the superior surgical solution to the traditional spinal fusion because it maintains normal motion of the spine and in many cases lessens the chance of future surgery. However, the designs of the first-generation artificial discs, much like total hip replacement, were based on the ball-and-socket concept which does not take into account the natural compression of the native disc,&#8221; said Dr. Richard D. Guyer, orthopedic spine surgeon and Chairman of the Texas Back Institute Research Foundation in Dallas and an investigator in the &#8220;Restore&#8221; U.S. clinical trial sponsored by Spinal Kinetics. &#8220;The M6 disc is designed out of materials to mimic the biomechanics of a normal disc including axial compression, flexion-extension, lateral bending, translation and axial rotation in order to provide patients with a more natural range of motion.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The M6 artificial discs currently have CE Mark approval for distribution in the European Union and other international geographies. They are not available for commercial distribution in the U.S. Spinal Kinetics has submitted a PMA to the U.S. Food and Drug Administration in order to gain U.S. market approval for the M6-C cervical disc to treat single level cervical DDD. Internationally, there have been more than 54,000 implants of the M6-C and M6-L since the products were first launched in 2006.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:-4.17%;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3451 Plano Parkway</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lewisville, TX 75056 USA</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel&nbsp;&nbsp; 214 937 2000</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><img src="g2018031519270965211068.jpg" title="" alt="" style="width:258px;height:40px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We look forward to becoming a part of the Orthofix team,&#8221; said Tom Afzal, President and CEO of Spinal Kinetics. &#8220;Joining forces gives us the opportunity to bring together Spinal Kinetics</font><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217; proven</font><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> innovative technology</font><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with Orthofix&#8217;s regulatory, market development, distribution and commercial expertise as we work to broaden the availability of these devices and ultimately prepare for U.S. commercialization.&#8221;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix estimates the artificial disc market in 2017 to be over $325 million worldwide and $200 million in the U.S., with double-digit growth expected for many years. Also, Orthofix anticipates that the momentum created from the addition of the M6 disc to the Orthofix spine fixation portfolio will generate pull-through revenue of other Orthofix products and position the company for market share gains in the $5.4 billion U.S. spine hardware market.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction is anticipated to close in the second quarter of 2018, subject to customary closing conditions. Orthofix expects the acquisition to not only add revenue in 2018, but also increase its organic revenue growth rate in 2019 and beyond. The company also expects the deal to be slightly accretive to the Company&#8217;s non-GAAP diluted earnings per share and adjusted EBITDA within 12 months of PMA approval in the U.S. and further accretive thereafter. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the transaction, Canaccord Genuity is acting as a financial advisor to Spinal Kinetics.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Orthofix Conference Call</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix will conduct a conference call on Thursday March 15 at 4:00 p.m. Central time (5:00 p.m. Eastern time). An overview of the transaction will be provided during the call. The investor presentation is viewable on Orthofix&#8217;s <font style="color:#0072C6;">U.S. corporate home page </font>or<font style="color:#0072C6;"> ir.orthofix.com</font>. Interested parties may access the conference call by dialing (844) 809-1992 in the U.S. and (612) 979-9886 outside the U.S., and referencing the conference ID 7493218. A replay of the call will be available for two weeks by dialing (855) 859-2056 in the U.S. and (404) 537-3406 outside the U.S., and entering the conference ID 7493218. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">About Orthofix</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orthofix International N.V.&#160;is a global medical device company focused on musculoskeletal healing products and value-added services. The Company&#8217;s mission is to improve patients' lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide. Headquartered in&#160;Lewisville,&#160;Texas, the Company has four strategic business units: BioStim, Extremity Fixation, Spine Fixation, and Biologics.&#160;Orthofix&#160;products are widely distributed via the Company's sales representatives and distributors. For more information, please visit&#160;<font style="color:#0072C6;">www.orthofix.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">About Spinal Kinetics Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Founded in 2003, Spinal Kinetics is a privately held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine. The M6-C cervical and M6-L lumbar artificial discs have rapidly established themselves among the leading artificial discs available due to the unique biomechanical properties that replicate the motion of a natural disc and the positive clinical outcomes for patients. The company is located in Sunnyvale, California. For more information about Spinal Kinetics or the M6 Artificial Disc, please visit <font style="color:#0072C6;">spinalkinetics.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Forward Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the estimates, projections, financial condition, results of operations and businesses of Orthofix and its subsidiaries, Spinal Kinetics and their respective companies&#8217; product portfolios, are based on Orthofix management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The forward-looking statements in this release do not constitute guarantees or promises of future performance. Factors that could cause or contribute to such differences may include, but are not limited to risks, including the possibility that the deal might not close, difficulties commercializing Spinal Kinetics&#8217; products and integrating their product lines into Orthofix&#8217;s business, inaccuracies in Orthofix&#8217;s estimates and projections of future product sales, including the current and future size of the worldwide and U.S. artificial disc market, FDA and regulatory approval risks, and other risks described in the "Risk Factors" section of our 2017 Annual Report on Form 10-K, as well as in other reports that we file in the future. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g2018031519270965211068.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031519270965211068.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[@ .061O8F4 9      !_^$+C$5X:68
M $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $
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M2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M245#('-21T(               $  /;6  $     TRU(4" @
M                                                   18W!R=
M 5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA9
M6@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P
M9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@
M   4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M!#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@
M2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#
M-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                         %A9
M6B        #S40 !     1;,6%E:(                     !865H@
M    ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@
M   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                        9&5S8P         N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="                             &1E<V,         +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ                                  !V:65W       3I/X
M%%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE
M87,          0                        */     G-I9R      0U)4
M(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\  $0@
M8P)Y P$1  (1 0,1 ?_$ !\  0 # 0$! 0$  P         )"@L(!@<%! $"
M __$ % 0   & @$" P(("@0,! <   $" P0%!@ '"!()$1,*%!4A%K=8>-@Y
M&B(C%U=WEQ@XJ+@QE-;703)")+56MC>(Z!EI43/5F&%2-$0F)Z?_Q  = 0$!
M  (# 0$!            " <)! 4& P$"_\0 /!$  @$# @0% @,%!@<!
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MS3/W\XYR1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M:_[IT:=4TFFCUV<,YHP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M6L5K?FS=T 6=I>\JQJ+4S1D)&ZH)HN 3N>_:C(^2_(/F)![/Y@$#\:5,WX.
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M12(F55M(+-P47( J !512 X\D/6F=JMF]<-6VD^><L@@H)$Y&/U3H5-D\*
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M1TQOQN+5.7N5400ND>U\LB43L&NKKUV\QZ;8BJJC5F6RQCE5F53I4.P504$
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M-\Q@VV]Y8KB9WOIINX,W:(S%AE&Z:TEN6DQQ@,J_2?%<6=--0ZK=X[\E&-5
MTJZ7<ZEL>GU78-!LD+<:->*[#6ZG6VN2+:7K]GJ]BCF\O S\'*LE%FDC$R\8
M[2<-UTC&3524*8HB X!XG?6]=5\9--;)Y ;OMT?1-4:EJ<I<[Q:9+S3HQL-%
M)=9DVK1N15[*S$DY.FT8,&R:KR0?+HMFZ:BZJ9# 97_=C]31S;Y\7"W4/0-W
MN7%#B3[<^C*[1->S!JSM#8$ DX42:S.W=B5]P6P>U33/Q,YK\2^0@D4E?9EP
MD3)@[4 K3K+*N%55UU5%UUU#K+++',HJLJH83J*JJ'$QU%%#F$3&$1$1'Q'
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M'L;?DM <7Z)-MG MGD0[VHQGG=UD(]8A!72EF^IJM8A9+)'25:N_*7(<#)
M@8^^ =@\#.$NY.X=RHU9Q/T8S:FN6R990KZP2I7 5NAT^)0/(VZ_6I=LFHLC
M U:%147.0@"N[6\IJ@4[A=%,P&LWV[.PSVZ>W12Z\UI&DJCN#=#-JR7LW(O=
M57@;OLF7L*2( ]D*D6::2,5JN%47$P(1\ FU$K<J8.UWK@IG2@$SF ?SNVC5
M^U<L7S9N]8O6ZS1XS=HIN6KMJY3,BX;.6ZQ3HKMUT3B0Y#@)3%$0$! < HO^
MKY[;G#K6_$.B\U]1Z3H^H-\I<@Z7K.W3NLZ_&TV'V-4+E4-@R+H+G6H!"/@I
M2T1DO6&2C69,A[P]G!5LLHJD9'R ,Z_ +<OHQ;C8(7NF;0J3!\H2O7;AYLD+
M!&&,H+5VYKFR=02D)(>450B?O"-447224,!NA!VN4 #S/$ -1/ & 1 =_C[&
MWN$_H E_].P. 8PV =_]IW[4WMI_3_X;_P Q6N< V^< 8 P#-$];1^_UQ1^B
M W^6?:. 4PL T^_14_99;\^G_M/^77BK@%OW & <_P#++]UCDO\ 1_W+\G5C
MP#"'P#K_ +>W[_7![Z7_ !I^6>E8!I\^J'[AUAX(=MF=K.LIM:"W9RUL2V@Z
M7+,'!F\O5:6^A'TKMVZQBI%4'"#IC4T20K=PB<'#*0GVKE/X4?$ ,D? /NO&
M/CGM'EUR!U'QHTM#%GMG[GNT12*FR64.@P;NI)43O9J9=II+&85VMQ*+B1DG
M/08&K!JLJ("!!# -@#M1]E?B#VI]75^.UO38.^\BGD&@CM/D]:H-FYV+;9MT
MVZ9UE47#P7RVM-=G64,BU@XM5,BC5)$T@J_>%4=J 3!X P#C3FUV_P#B7W#=
M32.GN5NH*WL>#59OTJU9E&B##8FN)5ZCY9++K:\MT1G:C.-E2D4'R%!:/ 3!
M%X@Y;&40.!D ]VCMK[%[5?,N[\8+M*J6VL^[V-]TWL@8\8Q+8^I;&[D6U>L"
MK'J4383D=(1+R*EFZ9SI(RD>X!(ZB I*' C0P#1F]&-W"K#LK5F[^W7L:>=3
M#_1#%+=V@A?NA=.V.I[-8$(+9M/;@JJ!VT#3=ASL5(,RE*I^-M#D@F3320((
M'C_6M<V9JMTGC!P!J$XZCV^R#2?(W=4>S=J-32M6K$HO4-.PLBFB(>\H&1N#
M6PR*K=;\260@6*P%,HD0R8&>3@%GKTVW8ZK/=/VG?MT\D26!MP_X_P I$0<U
M"P+YW!R.Z]JR3=.:;ZU;6-F4KN&J];KQT7]D7:+(28(R,>W:'2,[4=M -0;0
M/%WCAQ6I[6@\;M&:KT?46K=%O[FUE2("I)OO)* >US3J(8MG]@E%SAUKO'RK
MAVX5$5%5#G,8P@?>, 8 P!@&8)ZU;[4W0?T -6?S%<JL J!8!H]^B&_=9YP_
MI_UW\G3C +ON 4F_4L>G?1Y&L;]W$>$554)R%BX]6R<AM&UR-7<!O:,BF:9'
MNQ=>P\:@JH3<D='M@/)QR*?3:44S+I@$N4X2P&;:<ATSF34*8AR&,0Y#E$IR
M'*(E,4Q3  E,40\! ?A < F2[+O>)W+VC>19+I!IR5]X[['6C87D!I$\HX;,
M;'").4P;WBHI*+>[(O:5-0,H:.=JIBFZ;*+L5Q(DX\Y$"<7U%WJ1X/EU4"<*
MNWU<Y@O'2UUN*D>06YTXZ0KDOMY"P1D7-,]05IC*-V5@KM'@TW(HV@SE%N\F
M)$IX[H3CVSCWJ!2FP"S7Z>SL'VWN>[+:;\Y"0EBJ? _6\T<LU*)J.8.5Y!V^
M'=)>9JZB2)!1?(55HL4Q;+.M! S4A18,U2/U3N(\#5KJ%1J] JE:HM)@(FJ4
MVFP,35ZI6(%BA&0E>KL"P0BX:%B(YJ1-LQC8R.:IHHI$*!$TR  !X!@'"7.3
M@.RY8&BK[0-A,],;Z@=?WO3JUOFJ!%;9U=M[0>TTFZ&S^-_)/3<O*UYCMW2E
MU*U(L#0LE%RL+(A[9&/FIU'1'0'&$QVJ=V\DK'14.7=QXB4/5E"U6SX_R%6X
M/Z!NVL-G;;XY,W;)Z?C7;-[[(V?=K;KGCA,JQJ2<I5*HU9O)!J=5N,PF@JJF
MH!+]^SUH+\QVG_U:4O\ ]%P#_]2&^0?NY1^]DY!<[I_(NW+]ZY4Z?,<.WBQW
M#E<_2!2]:RRAC#X  >(YM^MVX6;=NU;C2W&*27DDJ)?DC3)<N3O7+EV[*MR4
MFV_-MU;_ #9_)GT/X& 2(]J#=B>@^X)QIN;UY['!35[2UI9#J*%3:!#;38NZ
M"+J0.8Q"E8P\E/MI YA'P(+0##X@7P'&O=_0GN'MSNG!A#JR(8_OP\^JPU>H
MO6482@O/JH9/[,Z^MM]R]IY]R?3CW,GV+GETY"=FLO2,IQF_+IJ:06:QS:>,
M _+FX6*LD++UV>8-Y6#GXM_"S,8\)YC21BI1HJQD6#I/Q#S&[QFN=,Y?\)3"
M&?6Q?O8M^SDX]QPR+<U*,ESC*+K%KU32:/CD6+.58OXN3;4\>Y!QE%\I1DFI
M)^C3:9F5<WN.3WB9RLW9H)Q[0I'42Y.B51XZ\3+R5$GF[:R46174^$BCMU4Y
M=F+CI$P%<^83Q\2CFT_8>YH;PVCH6XHT5S(L+W$N4;L&X74O17(RI^FC\34Q
MW VM<V7O+7]MRJ[6-??MM\Y69I7+,GZNW*/5Y2JO Y5SUQXX8 P"??TX]O6@
M.>EEKO6/LMZX_7N&,CTF,07D19Z):&KCQ*8H$41;0K@@&-XEZ5C!X>(@(3O\
MF<*.1V]Q<FGUX^I6I5])6[MMK\W)/\D4E\6LYXW<?+Q:_1D:9>C3UC<LW$_R
M4)+\V7G,@4V&%8SU=.QY.C=FK8%<CU%DT-O[UT3KB7\H \#QC"R/-J@FL854
MS$1/):Q;>(E XB/@42](B8H&3U@$@?:CT?!\D>Y7P:TK:F;.2J%XY-ZD;W.)
MD$$G+.;I4+;8^R7&"<(+B"*B<Y689TT_# Y0\[Q$A_\ $,!MZX P!@# (4?4
M4Z<B-U]F;G/!R;5NLZI.KV6XX)VL4@K1<OIVV5_89G3)4X@*#AW$0#MD<2CU
M';NU$_A X@(&-K@'NM7WZ8U3LO7>T:\HLE/ZVO52OT&JW<BS<)S%.GX^PQBB
M#P$EQ:K$>QQ!*H!#]!O W2/AX8!H=>M[N3ICQCX,:](HX!G9]\;,N3A$J;<6
MIW5$U]&PC1194P>UD<));&7!(I!\LQ3J"?X2IX!G%X!/YZ??NJ<9^TCOS>6^
M=]ZBVKM.P7S4L;JK7RFK6],6=5R.?VV/M5V4E#W"S5PB)956KPY$1;"J<P(J
M ?I#PZ@+7_WVC@+\U'E__5],?WHX ^^T<!?FH\O_ .KZ8_O1P#Q=P];MQ)9-
M#GH'"CD79GP-S&3;7"ZZTHS0SKS"@5$[V%<[#6(W%$1,*H-S& P 7RQ >H *
MI'>.[\_)CO!.Z94;I3*KH_CSK6Q.+?2-*4^5D;0LXMZ\6[A4KCL&\2K2)4N%
MFB8>4>LF!VL9#LFC1ZN4K45555E (+\ T(O1B=NR^4YMNSN2[)KSJ KVR*:M
MH+CN649'2<VRM%ML98-L[ CBN )T0*=DI<7"Q[M(#>U.&THEXD*C^. OK8 P
M"(#O\?8V]PG] $O_ *=@< QAL [_ .T[]J;VT_I_\-_YBM<X!M\X P!@&:)Z
MVC]_KBC]$!O\L^T< IA8!8&[4GJ(>3G:2X\7+CCI?26B-DU:Z[HL6[7\YM!+
M8)Y]I/V.CZZHCJ)9C5+G78[W.A':W:K)]:!EO.75\3B7H*4"3?[[1SZ^:CQ
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MU9)KHMI39W%I>:KAUC"4SY_KK95.6?1#;\+P.Z5AK4X>=/3_ .2Q4'Q#I\#
M:9. , 8 P"C=ZWO:$5'<<^#&ES+MS3EQW7LW:";8"];M&*UK18RJ+KG.5T7V
M9NX>;73*4#HG\\R1N@Y/).4X&<Q@%B#TJ]7EI_OB\2):.2*HSH]=Y(6B>.8%
MA%")=\:-M4M%4GE(JD PSMO9$_&&3)X''P,)^DA@/.^J.^W7YS?\,W\GG'W
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M>X;GM$3[2"9#L8>1K$!#MG[<JI57!I5IYA#-UTS@0!^J.^W7YS?\,W\GG'W
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M[0]2;2,E([;UA3H@K9/9]?3\QX_G]S5=FS!2:()#.[2R,JZ\PTDV*E) 9Y.
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M(H^T*TPL.R]!.X!]/T"SQ=KAF<XUC>,L3(N8=S(Q*9'*;=TV6.B8P$53,('
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M[4]R\SMSKOOSZKN@9+4<FTN+:7*[!-I>Y;JZ5:4HN4'2JE'$W=WM?A=R]O\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MQC!'7V>,/;C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8!__]._Q@# & , 8 P"(IY[J_ZG</Y_[/\ \</B/_G_
M .TW\<_VF_BW\8;/\6_V-_=O_P"B_P DWLO_ )_NW_\ +/;?;/?O^<>&9EA[
MW_Y5>Z?ZC]E]QP^Q]K['KZ+?7_4NK_5_<5Y=?^GZ>C[?Z3"4_9__ %RQU?TS
M[[[?C]_[OW_M]=SV_P"F=/\ I/MJ<_;_ -1U^Y]S]1+KF&C-HP!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g2018031519270960711067.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031519270960711067.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I 0,# 2(  A$! Q$!_\0
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00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
